MEI Pharma, Inc. (MEIP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
11455 EL CAMINO REAL SAN DIEGO, CA 92130 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2024 Q2 | 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 26,900 | 38,300 | 56,600 | 59,500 | 82,200 | 100,693 | |||
| Cash and cash equivalent | 6,952 | 3,705 | 2,368 | 5,174 | 3,372 | 16,906 | |||
| Short-term investments | 19,953 | 34,640 | 54,184 | 54,306 | 78,830 | 83,787 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | (5) | (45) | 48 | 20 | (2) | ||||
| Prepaid expense | 248 | 1,374 | |||||||
| Contract with customer, asset, after allowance for credit loss | 85 | ||||||||
| Other undisclosed current assets | 597 | 1,095 | 2,766 | 6,672 | 6,222 | 6,750 | |||
| Total current assets: | 27,745 | 40,769 | 59,366 | 66,172 | 88,422 | 107,528 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 214 | 10,836 | 11,222 | 11,600 | 11,972 | ||||
| Property, plant and equipment | 5 | 392 | 1,058 | 1,144 | 1,229 | 1,309 | |||
| Total noncurrent assets: | 5 | 606 | 11,894 | 12,366 | 12,829 | 13,281 | |||
| TOTAL ASSETS: | 27,750 | 41,375 | 71,260 | 78,538 | 101,251 | 120,809 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,872 | 8,355 | 8,564 | 7,023 | 7,509 | 18,595 | |||
| Accounts payable | 976 | 3,168 | 3,176 | 1,378 | 3,220 | 6,134 | |||
| Accrued liabilities | 1,896 | 5,187 | 5,388 | 5,645 | 4,289 | 12,461 | |||
| Deferred revenue | 317 | ||||||||
| Other undisclosed current liabilities | 1,052 | 1,015 | 1,055 | 1,428 | |||||
| Total current liabilities: | 2,872 | 8,355 | 9,616 | 8,038 | 8,564 | 20,340 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 10,615 | 11,012 | 11,326 | 75,845 | |||||
| Deferred revenue | 64,545 | ||||||||
| Operating lease, liability | 10,615 | 11,012 | 11,326 | 11,300 | |||||
| Total noncurrent liabilities: | 10,615 | 11,012 | 11,326 | 75,845 | |||||
| Total liabilities: | 2,872 | 8,355 | 20,231 | 19,050 | 19,890 | 96,185 | |||
| Equity | |||||||||
| Equity, attributable to parent | 24,878 | 33,020 | 51,029 | 59,488 | 81,361 | 24,624 | |||
| Additional paid in capital | 421,104 | 421,239 | 420,842 | 420,174 | 430,984 | 430,621 | |||
| Accumulated deficit | (396,226) | (388,219) | (369,813) | (360,686) | (349,623) | (405,997) | |||
| Total equity: | 24,878 | 33,020 | 51,029 | 59,488 | 81,361 | 24,624 | |||
| TOTAL LIABILITIES AND EQUITY: | 27,750 | 41,375 | 71,260 | 78,538 | 101,251 | 120,809 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2024 Q2 | 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 65,297 | 1,457 | ||||||
| Cost of revenue | ||||||||
| Gross profit: | 65,297 | 1,457 | ||||||
| Operating expenses | (8,352) | (29,911) | (9,829) | (11,930) | (10,016) | (12,537) | ||
| Other undisclosed operating income | 10,931 | |||||||
| Operating income (loss): | (8,352) | (18,980) | (9,829) | (11,930) | 55,281 | (11,080) | ||
| Nonoperating income | 345 | 574 | 702 | 867 | 1,093 | 2,654 | ||
| Investment income, nonoperating | 355 | 608 | 706 | 869 | 1,094 | |||
| Income (loss) from continuing operations: | (8,007) | (18,406) | (9,127) | (11,063) | 56,374 | (8,426) | ||
| Other undisclosed net loss | (1,603) | |||||||
| Net income (loss) available to common stockholders, diluted: | (8,007) | (18,406) | (9,127) | (11,063) | 56,374 | (10,029) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2024 Q2 | 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (8,007) | (18,406) | (9,127) | (11,063) | 56,374 | (10,029) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (8,007) | (18,406) | (9,127) | (11,063) | 56,374 | (10,029) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.